APPENDICES

APPENDIX 1 Patient #21

Figure I: Phenotype of #21 MSC after selection, analyzed by FACS.

MSC were negatively selected. Phenotypes displayed a clear similarity between MSC cultured alone and isolated from the different co-culture ratios and at different days. Cells were positive for CD90, CD105 and CD73, with a slightly decreased expression of CD105 at day 7 in all conditions.

Although MSC were supposed to be *lineage* negative, they were distinct from the negative control. This little positivity was similar to the one that we observed in MSC isolated from bone marrow after culture (data not shown), suggesting a likely induction of *lineage* genes *in vitro*.

APPENDIX 2

Patient #26



Figure II: Phenotype of patient #26 MSC after selection.

MSC phenotype was comparable between MSC cultured alone and after CD45 negative selection from all direct co-culture conditions.

APPENDIX 3

Patient #32



Figure III: Phenotype of patient #32 MSC after selection.

As for patients #21 and #26, MSC phenotype was comparable in all conditions and similar to control MSC cultured alone. The double peak observed for the CD90 attested to the likely heterogeneity of the MSC population of patient #32.

APPENDIX 4

Patient #32



Figure IV: Relative gene expression in N-MSC and TIC in co-cultures (Patient #32).

TIC were collected from transwell co-culture at day 3.

TIC displayed a distinct gene expression compared to either N-MSC in co-culture or control MSC. They highly overexpressed BST2, ITGA11 and MX2 compared to MSC.

References

[1] J Ferlay et al., "Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012," *International Journal of Cancer* 136, no. 5 (March 1, 2015): E359–86, doi:10.1002/ijc.29210.
[2] "Lung and Bronchus Cancer, CSR 1975-2013 - sect_15_lung_bronchus.pdf," accessed September 9, 2016, http://seer.cancer.gov/csr/1975_2013/results_merged/sect_15_lung_bronchus.pdf.
[3] V Kumar, A Abbas , J Aster, "Robbins Basic Pathology," 9th edition (Philadelphia, PA: Elsevier/Saunders, 2013, n.d.).
[4] O Auerbach, EC Hammond, and L Garfinkel, "Changes in Bronchial Epithelium in Relation to Cigarette Smoking, 1955–1960 vs. 1970–1977," *New England Journal of Medicine* 300, no. 8 (février 1979): 381–86, doi:10.1056/NEJM197902223000801.
[5] L Thiberville et al., "Evidence of Cumulative Gene Losses with Progression of Premalignant Epithelial Lesions to Carcinoma of the Bronchus," *Cancer Research* 55, no. 22 (November 15, 1995): 5133–39.
[6] Y Sekido, KM Fong, and JD Minna, "Molecular Genetics of Lung Cancer," *Annual Review of Medicine* 54, no. 1 (2003): 73–87, doi:10.1146/annurev.med.54.101601.152202.
[7] RL Siegel, KD Miller, and A Jemal, "Cancer Statistics, 2015," *CA: A Cancer Journal for Clinicians* 65, no. 1 (January 1, 2015): 5–29, doi:10.3322/caac.21254.
[8] "Cancer Facts & Figures 2015 - Acspc-044552.pdf," accessed March 28, 2016, http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf.
[9] Y Wang, G Schmid-Bindert, and C Zhou, "Erlotinib in the Treatment of Advanced Non-Small Cell Lung Cancer: An Update for Clinicians," *Therapeutic Advances in Medical Oncology* 4, no. 1 (January 2012): 19–29, doi:10.1177/1758834011427927.
[10] E Lasalvia-Prisco et al., "Randomized Phase II Clinical Trial of Chemo-Immunotherapy in Advanced Nonsmall Cell Lung Cancer," *Biologics : Targets & Therapy* 2, no. 3 (September 2008): 555–61.
[11] P Dalerba, RW Cho, and MF Clarke, "Cancer Stem Cells: Models and Concepts," *Annual Review of Medicine* 58, no. 1 (2007): 267–84, doi:10.1146/annurev.med.58.062105.204854.
[12] M Alamgeer et al., "Cancer Stem Cells in Lung Cancer: Evidence and Controversies," *Respirology (Carlton, Vic.)* 18, no. 5 (July 2013): 757–64, doi:10.1111/resp.12094.
[13] L MacDonagh et al., "Lung Cancer Stem Cells: The Root of Resistance," *Cancer Letters* 372, no. 2 (March 28, 2016): 147–56, doi:10.1016/j.canlet.2016.01.012.
[14] SL Wood et al., "The Role of the Tumor-Microenvironment in Lung Cancer-Metastasis and Its Relationship to Potential Therapeutic Targets," *Cancer Treatment Reviews* 40, no. 4 (mai 2014): 558–66, doi:10.1016/j.ctrv.2013.10.001.
[15] R Liu et al., "Mesenchymal Stem Cells in Lung Cancer Tumor Microenvironment: Their Biological Properties, Influence on Tumor Growth and Therapeutic Implications," *Cancer Letters* 353, no. 2 (October 28, 2014): 145–52, doi:10.1016/j.canlet.2014.07.047.
[16] HF Dvorak, "Tumors: Wounds That Do Not Heal--Redux," *Cancer Immunology Research* 3, no. 1 (January 2015): 1–11, doi:10.1158/2326-6066.CIR-14-0209.
[17] D Hanahan and LM Coussens, "Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment," *Cancer Cell* 21, no. 3 (March 20, 2012): 309–22, doi:10.1016/j.ccr.2012.02.022.
[18] B Psaila and D Lyden, "The Metastatic Niche: Adapting the Foreign Soil," *Nature Reviews. Cancer* 9, no. 4 (April 2009): 285–93, doi:10.1038/nrc2621.
[19] DF Quail and JA Joyce, "Microenvironmental Regulation of Tumor Progression and Metastasis," *Nature Medicine* 19, no. 11 (November 2013): 1423–37, doi:10.1038/nm.3394.
[20] M. Dominici et al., "Minimal Criteria for Defining Multipotent Mesenchymal Stromal Cells. The International Society for Cellular Therapy Position Statement," *Cytotherapy* 8, no. 4 (2006): 315–17, doi:10.1080/14653240600855905.

[21] MF Pittenger et al., "Multilineage Potential of Adult Human Mesenchymal Stem Cells," *Science* 284, no. 5411 (April 2, 1999): 143–47, doi:10.1126/science.284.5411.143.
[22] M Kéramidas et al., "The Dual Effect of Mesenchymal Stem Cells on Tumour Growth and Tumour Angiogenesis," *Stem Cell Research & Therapy* 4, no. 2 (April 29, 2013): 41, doi:10.1186/scrt195.
[23] J Stagg and J Galipeau, "Mechanisms of Immune Modulation by Mesenchymal Stromal Cells and Clinical Translation," *Current Molecular Medicine* 13, no. 5 (May 1, 2013): 856–67, doi:10.2174/1566524011313050016.
[24] E Spaeth et al., "Inflammation and Tumor Microenvironments: Defining the Migratory Itinerary of Mesenchymal Stem Cells," *Gene Therapy* 15, no. 10 (avril 2008): 730–38, doi:10.1038/gt.2008.39.
[25] KS Aboody, J Najbauer, and MK Danks, "Stem and Progenitor Cell-Mediated Tumor Selective Gene Therapy," *Gene Therapy* 15, no. 10 (March 27, 2008): 739–52, doi:10.1038/gt.2008.41.
[26] G Bassi et al., "CCR2-Dependent Recruitment of Macrophages by Tumor Educated Mesenchymal Stromal Cells Promotes Tumor Development and Is Mimicked by TNF-Alpha," *Cell Stem Cell* 11, no. 6 (December 7, 2012): 812–24, doi:10.1016/j.stem.2012.08.013.
[27] BG Cuiffo and AE Karnoub, "Mesenchymal Stem Cells in Tumor Development," *Cell Adhesion & Migration* 6, no. 3 (May 1, 2012): 220–30, doi:10.4161/cam.20875.
[28] CMF Gomes, "The Dual Role of Mesenchymal Stem Cells in Tumor Progression," *Stem Cell Research & Therapy* 4, no. 2 (April 29, 2013): 42, doi:10.1186/scrt189.
[29] S Gottschling et al., "Mesenchymal Stem Cells in Non-Small Cell Lung cancer—Different from Others? Insights from Comparative Molecular and Functional Analyses," *Lung Cancer* 80, no. 1 (April 1, 2013): 19–29, doi:10.1016/j.lungcan.2012.12.015.
[30] K Suzuki et al., "Mesenchymal Stromal Cells Promote Tumor Growth through the Enhancement of Neovascularization," *Molecular Medicine* 17, no. 7–8 (2011): 579–87, doi:10.2119/molmed.2010.00157.
[31] JG Casado, R Tarazona, and FM Sanchez-Margallo, "NK and MSCs Crosstalk: The Sense of Immunomodulation and Their Sensitivity," *Stem Cell Reviews and Reports* 9, no. 2 (February 10, 2013): 184–89, doi:10.1007/s12015-013-9430-y.
[32] J Guan and J Chen, "Mesenchymal Stem Cells in the Tumor Microenvironment," *Biomedical Reports* 1, no. 4 (July 2013): 517–21, doi:10.3892/br.2013.103.
[33] W Zhu et al., "Mesenchymal Stem Cells Derived from Bone Marrow Favor Tumor Cell Growth in Vivo," *Experimental and Molecular Pathology* 80, no. 3 (juin 2006): 267–74, doi:10.1016/j.yexmp.2005.07.004.
[34] M Valtieri and A Sorrentino, "The Mesenchymal Stromal Cell Contribution to Homeostasis," *Journal of Cellular Physiology* 217, no. 2 (November 1, 2008): 296–300, doi:10.1002/jcp.21521.
[35] M Llamazares et al., "The ADAMTS12 Metalloproteinase Exhibits Anti-Tumorigenic Properties through Modulation of the Ras-Dependent ERK Signalling Pathway," *Journal of Cell Science* 120, no. 20 (October 15, 2007): 3544–52, doi:10.1242/jcs.005751.
[36] AG Beristain, H Zhu, and PCK Leung, "Regulated Expression of ADAMTS-12 in Human Trophoblastic Cells: A Role for ADAMTS-12 in Epithelial Cell Invasion?," *PLoS ONE* 6, no. 4 (April 11, 2011), doi:10.1371/journal.pone.0018473.
[37] J Walter-Yohrling et al., "Identification of Genes Expressed in Malignant Cells That Promote Invasion," *Cancer Research* 63, no. 24 (December 15, 2003): 8939–47.
[38] EH Yi et al., "BST-2 Is a Potential Activator of Invasion and Migration in Tamoxifen-Resistant Breast Cancer Cells," *Biochemical and Biophysical Research Communications* 435, no. 4 (juin 2013): 2, doi:10.1016/j.bbrc.2013.05.043.
[39] XW Wang et al., "Increased Expression of Chitinase 3-like 1 Is a Prognosis Marker for Non-Small Cell Lung Cancer Correlated with Tumor Angiogenesis," *Tumor Biology* 36, no. 2 (October 12, 2014): 901–7, doi:10.1007/s13277-014-2690-6.
[40] M Kawada et al., "Chitinase 3-like 1 Promotes Macrophage Recruitment and Angiogenesis in Colorectal Cancer," *Oncogene* 31, no. 26 (June 28, 2012): 3111–23, doi:10.1038/onc.2011.498.
[41] Y Feng et al., "Expression of VEGF-C and VEGF-D as Significant Markers for Assessment of Lymphangiogenesis and Lymph Node Metastasis in Non-Small Cell Lung Cancer," *The Anatomical*

Record: Advances in Integrative Anatomy and Evolutionary Biology 293, no. 5 (mai 2010): 802–12, doi:10.1002/ar.21096.
[42] JL Solan, SR Hingorani, and PD Lampe, "Changes in Connexin43 Expression and Localization During Pancreatic Cancer Progression," *The Journal of Membrane Biology* 245, no. 5–6 (June 2012): 255–62, doi:10.1007/s00232-012-9446-2.
[43] MS Mulvihill et al., "Gremlin Is Overexpressed in Lung Adenocarcinoma and Increases Cell Growth and Proliferation in Normal Lung Cells," *PLoS ONE* 7, no. 8 (August 1, 2012), doi:10.1371/journal.pone.0042264.
[44] TJ Bayliss et al., "A Humanized Anti-IL-6 Antibody (ALD518) in Non-Small Cell Lung Cancer," *Expert Opinion on Biological Therapy* 11, no. 12 (décembre 2011): 1663–68, doi:10.1517/14712598.2011.627850.
[45] W Chen et al., "The CCL2/CCR2 Axis Enhances IL-6-Induced Epithelial-Mesenchymal Transition by Cooperatively Activating STAT3-Twist Signaling," *Tumor Biology* 36, no. 2 (October 16, 2014): 973–81, doi:10.1007/s13277-014-2717-z.
[46] CQ Zhu et al., "Integrin α11 Regulates IGF2 Expression in Fibroblasts to Enhance Tumorigenicity of Human Non-Small-Cell Lung Cancer Cells," *Proceedings of the National Academy of Sciences of the United States of America* 104, no. 28 (July 10, 2007): 11754–59, doi:10.1073/pnas.0703040104.
[47] R Navab et al., "Integrin α11β1 Regulates Cancer Stromal Stiffness and Promotes Tumorigenicity and Metastasis in Non-Small Cell Lung Cancer," *Oncogene* 35, no. 15 (April 14, 2016): 1899–1908, doi:10.1038/onc.2015.254.
[48] L Wei et al., "Lysyl Oxidase May Play a Critical Role in Hypoxia-Induced NSCLC Cells Invasion and Migration," *Cancer Biotherapy & Radiopharmaceuticals* 27, no. 10 (December 2012): 672–77, doi:10.1089/cbr.2012.1241.
[49] Q Xiao and G Ge, "Lysyl Oxidase, Extracellular Matrix Remodeling and Cancer Metastasis," *Cancer Microenvironment* 5, no. 3 (April 13, 2012): 261–73, doi:10.1007/s12307-012-0105-z.
[50] MC King, G Raposo, and MA Lemmon, "Inhibition of Nuclear Import and Cell-Cycle Progression by Mutated Forms of the Dynamin-like GTPase MxB," *Proceedings of the National Academy of Sciences of the United States of America* 101, no. 24 (June 15, 2004): 8957–62, doi:10.1073/pnas.0403167101.
[51] K Melén et al., "Human MxB Protein, an Interferon-A-Inducible GTPase, Contains a Nuclear Targeting Signal and Is Localized in the Heterochromatin Region beneath the Nuclear Envelope," *Journal of Biological Chemistry* 271, no. 38 (September 20, 1996): 23478–86, doi:10.1074/jbc.271.38.23478.
[52] S Cal et al., "Identification, Characterization, and Intracellular Processing of ADAM-TS12, a Novel Human Disintegrin with a Complex Structural Organization Involving Multiple Thrombospondin-1 Repeats," *Journal of Biological Chemistry* 276, no. 21 (May 25, 2001): 17932–40, doi:10.1074/jbc.M100534200.
[53] H Peinado, S Lavotshkin, and D Lyden, "The Secreted Factors Responsible for Pre-Metastatic Niche Formation: Old Sayings and New Thoughts," *Seminars in Cancer Biology*, The Biology of Cancer Metastasis, 21, no. 2 (avril 2011): 139–46, doi:10.1016/j.semcancer.2011.01.002.
[54] E Segal and J Widom, "From DNA Sequence to Transcriptional Behavior: A Quantitative Approach," *Nature Reviews. Genetics* 10, no. 7 (July 2009): 443–56, doi:10.1038/nrg2591.
[55] S Liu et al., "Breast Cancer Stem Cells Are Regulated by Mesenchymal Stem Cells through Cytokine Networks," *Cancer Research* 71, no. 2 (January 15, 2011): 614–24, doi:10.1158/0008-5472.CAN-10-0538.
[56] K McLean et al., "Human Ovarian Carcinoma–associated Mesenchymal Stem Cells Regulate Cancer Stem Cells and Tumorigenesis via Altered BMP Production," *The Journal of Clinical Investigation* 121, no. 121(8) (August 1, 2011): 3206–19, doi:10.1172/JCI45273.